Silver Book Fact

A study of rasagiline mesylate in Parkinson’s disease patients showed improved motor fluctuations and other Parkinson’s disease symptoms.

Parkinson Study Group. A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations. Arch Neurol. 2005; 62(2): 241-8. http://archneur.ama-assn.org/cgi/content/full/62/2/241

Reference

Title
A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations
Publication
Arch Neurol
Publication Date
2005
Authors
Parkinson Study Group
Volume & Issue
Volume 62, Issue 2
Pages
241-8
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • According to one Parkinson’s expert, a 10% slowing of Parkinson’s disease progression would save $327 million per year.  
  • An Alzheimer’s treatment breakthrough that slowed disease progression and began to show effects in 2015, would reduce Medicaid costs for people with the disease by $62 billion–from the expected $178…  
  • If the progression of Parkinson’s disease were slowed by 50%, there would be a 35% reduction in excess costs.  
  • Impact of a 5-Year Delay in Onset by Stage of Disease, Americans Age 65 and Older with Alzheimer’s Disease, 2050  
  • In a study of different treatments for Parkinson’s disease, results showed that the disease can be managed for up to 5 years with a reduces risk of dyskinesia.